ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Phthalimide → tert-butyl 4-(1-(4-chlorophenyl)-3-(1,3-dioxoisoindolin-2-yl)propylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate

HRID 423056
印刷

反応式

HRID 423056 の反応式
C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.[C:20]1(=[O:30])[NH:24][C:23](=[O:25])[C:22]2=[CH:26][CH:27]=[CH:28][CH:29]=[C:21]12.[Cl:31][C:32]1[CH:37]=[CH:36][C:35]([CH:38]([NH:42][C:43]([C:45]2([NH:60][C:61](=[O:67])[O:62][C:63]([CH3:66])([CH3:65])[CH3:64])[CH2:50][CH2:49][N:48]([C:51]3[C:52]4[CH:59]=[CH:58][NH:57][C:53]=4[N:54]=[CH:55][N:56]=3)[CH2:47][CH2:46]2)=[O:44])[CH2:39][CH2:40]O)=[CH:34][CH:33]=1.N(C(OCC)=O)=NC(OCC)=O>C1COCC1>[Cl:31][C:32]1[CH:33]=[CH:34][C:35]([CH:38]([NH:42][C:43]([C:45]2([NH:60][C:61](=[O:67])[O:62][C:63]([CH3:66])([CH3:65])[CH3:64])[CH2:46][CH2:47][N:48]([C:51]3[C:52]4[CH:59]=[CH:58][NH:57][C:53]=4[N:54]=[CH:55][N:56]=3)[CH2:49][CH2:50]2)=[O:44])[CH2:39][CH2:40][N:24]2[C:20](=[O:30])[C:21]3[C:22](=[CH:26][CH:27]=[CH:28][CH:29]=3)[C:23]2=[O:25])=[CH:36][CH:37]=1
参加物反応条件実験手順後処理出典と根拠反応ノート

参加物

6

反応物 4

HCID 6809PhthalimideHCID 11776TriphenylphosphineHCID 220568ethyl N-ethoxycarbonyliminocarbamateHCID 57750387tert-butyl 4-(1-(4-chlorophenyl)-3-hydroxypropylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate2 回

生成物 1

HCID 57750333
tert-butyl 4-(1-(4-chlorophenyl)-3-(1,3-dioxoisoindolin-2-yl)propylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate
収率 21.23%

試薬・触媒・溶媒 1

HCID 8028Tetrahydrofuran溶媒

反応条件

温度
0 °C

実験手順

Triphenylphosphine (158 mg) and phthalimide (22.11 mg) were added in one portion to a stirred solution of tert-butyl 4-(1-(4-chlorophenyl)-3-hydroxypropylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate (Intermediate 36) (53 mg) dissolved in THF (10 mL) and cooled to 0° C. under argon. The resulting solution was stirred at 0° C. for 30 minutes. Diethyl azodicarboxylate (0.093 mL) was added dropwise at 0° C. under argon. The resulting suspension was stirred at 0° C. for 60 minutes and overnight at room temperature. The suspension was quenched with water. The THF was removed in vacuo and the aqueous phase extracted with DCM. The organic phase was dried and concentrated to provide crude product. The crude product was purified by flash chromatography on silica gel eluting with 0 to 10% methanol in DCM. The solvent was evaporated to dryness to afford tert-butyl 4-(1-(4-chlorophenyl)-3-(1,3-dioxoisoindolin-2-yl)propylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate as a white solid (14.00 mg, 21.23%).

後処理

  1. stirringThe resulting suspension was stirred at 0° C. for 60 minutes and overnight at room temperature
  2. customThe suspension was quenched with water
  3. customThe THF was removed in vacuo
  4. extractionthe aqueous phase extracted with DCM
  5. customThe organic phase was dried
  6. concentrationconcentrated
  7. customto provide crude product
  8. customThe crude product was purified by flash chromatography on silica gel eluting with 0 to 10% methanol in DCM
  9. customThe solvent was evaporated to dryness

出典と根拠

ORDレコード
ord-1a88c7fb38774fa2a7b7c864b3e52e87
出典データセット
uspto-grants-2012_01
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08101623B2

反応ノート

このページの内容参加物反応条件実験手順後処理出典と根拠反応ノート